Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 15/20 | 0.54 |
| ▸ | PTGS1 | P23219 | 3/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | RAB9A | P51151 | 2/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 2/20 | 0.42 |
| ▸ | GLA | P06280 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7216261 | 0.96 | PTGS2 (0.52) | PTGS2PTGS1KDM4EALDH1A1RAB9A | |
| SCHEMBL7221442 | 0.87 | ROCK2 (0.46) | PTGS2KDM4EALDH1A1RAB9ANPC1 | |
| SCHEMBL7216630 | 0.86 | PTGS2 (0.50) | PTGS2KDM4EALDH1A1RAB9ANPC1 | |
| SCHEMBL7220911 | 0.84 | PTGS2 (0.50) | PTGS2PTGS1KDM4EALDH1A1RAB9A | |
| SCHEMBL5263568 | 0.84 | MAPT (0.48) | PTGS2PTGS1KDM4EALDH1A1RAB9A | |
| SCHEMBL7215555 | 0.83 | KDM4E (0.60) | PTGS2PTGS1KDM4EALDH1A1RAB9A | |
| SCHEMBL5261561 | 0.83 | KDM4E (0.59) | PTGS2PTGS1KDM4EALDH1A1RAB9A | |
| SCHEMBL7220519 | 0.83 | KDM4E (0.59) | PTGS2PTGS1KDM4EALDH1A1RAB9A | |
| SCHEMBL5264827 | 0.82 | ALDH1A1 (0.56) | KDM4EALDH1A1RAB9ANPC1GAA | |
| SCHEMBL5262649 | 0.82 | ALDH1A1 (0.54) | PTGS2KDM4EALDH1A1RAB9ANPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1660500-B1 | SUBSTITUTED IMIDAZOPYRIMIDINES FOR THE PREVENTION AND TREATMENT OF CANCER | S A L V A T LAB SA (ES) | 2007-12-12 | — | — | EP | disclosed |
| US-20060189631-A1 | Substituted imidazopyrimidines for the prevention and treatment of cancer | LABORATORIOS S.A.L.V.A.T., S.A. (ES) | 2006-08-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060189631-A1 | Substituted imidazopyrimidines for the prevention and treatment of cancer | BRCA1, CCNA1, DPYD | PTGS2 1467/4885PTGS1 596/4885KDM4E 3211/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.